Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
2(18%)
Results Posted
78%(7 trials)

Phase Distribution

Ph phase_1
2
18%
Ph phase_3
5
45%
Ph phase_2
4
36%

Phase Distribution

2

Early Stage

4

Mid Stage

5

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
2(18.2%)
Phase 2Efficacy & side effects
4(36.4%)
Phase 3Large-scale testing
5(45.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

9 of 9 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

11

all time

Status Distribution
Active(2)
Completed(9)

Detailed Status

Completed9
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
11
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (18.2%)
Phase 24 (36.4%)
Phase 35 (45.5%)

Trials by Status

completed982%
recruiting218%

Recent Activity

2 active trials
Showing 5 of 11
recruitingphase_3

A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years)

NCT06579755
completedphase_2

A Study of Dengue Tetravalent Vaccine (TDV) in Healthy Participants in Japan

NCT06741683
completedphase_3

A Study of Dengue Vaccine in Healthy Children, Teenagers and Adults in India

NCT06060067
completedphase_2

Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults

NCT03746015
recruitingphase_3

A Study of 2 Doses of Tetravalent Dengue Vaccine (TDV) in Infants and Toddlers

NCT06665035
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT06579755Phase 3

A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years)

Recruiting
NCT06741683Phase 2

A Study of Dengue Tetravalent Vaccine (TDV) in Healthy Participants in Japan

Completed
NCT06060067Phase 3

A Study of Dengue Vaccine in Healthy Children, Teenagers and Adults in India

Completed
NCT03746015Phase 2

Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults

Completed
NCT06665035Phase 3

A Study of 2 Doses of Tetravalent Dengue Vaccine (TDV) in Infants and Toddlers

Recruiting
NCT02948829Phase 2

Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children

Completed
NCT01511250Phase 2

Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years

Completed
NCT03525119Phase 3

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Co-administered With an Hepatitis A Virus Vaccine

Completed
NCT03342898Phase 3

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults

Completed
NCT01765426Phase 1

Phase 1b Study Investigating Safety & Immunogenicity of TDV Given Intradermally by Needle or Needle-Free PharmaJet Injector

Completed
NCT01728792Phase 1

Impact of SC vs IM Administration of DENVax (TDV) on Safety and Immunogenicity

Completed

All 11 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
11